MeiraGTx Q2 2025 Earnings Report

MeiraGTx EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.52
• Beat/Miss: N/A
• One Year Ago EPS: N/A

MeiraGTx Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $8.00 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

MeiraGTx Announcement Details

• Quarter: Q2 2025
• Date: 8/11/2025
• Time: Before Market Opens
• Conference Call Date: Tuesday, August 12, 2025
• Conference Call Time: 9:30AM ET

MeiraGTx (NASDAQ:MGTX) is a clinical-stage gene therapy company dedicated to discovering, developing and commercializing novel treatments for patients with severe inherited and acquired diseases. The company’s expertise spans vector design, novel gene therapy constructs and scalable manufacturing, with the goal of delivering durable, one-time treatments that address the underlying genetic causes of disease rather than merely managing symptoms.

The company’s pipeline includes programs in ophthalmology, targeting inherited retinal diseases such as retinitis pigmentosa and Leber congenital amaurosis, as well as regenerative medicine and neuroscience indications. In addition to its vision-focused candidates, MeiraGTx is advancing gene therapy approaches for chronic pain and gastrointestinal disorders. These programs leverage both adeno-associated virus (AAV) platforms and mRNA delivery technologies to achieve sustained therapeutic benefit.

Headquartered in London, U.K., and Cambridge, Massachusetts, MeiraGTx operates cGMP-compliant manufacturing facilities in both regions, supporting both early-stage research and late-stage clinical production. The company was founded in 2015 and began trading publicly on the NASDAQ stock exchange under the symbol MGTX in 2019. MeiraGTx collaborates with academic institutions and clinical centers around the world to conduct its trials and expand access to its investigational therapies.